Impax Laboratories News

Endo Health Solutions Inc. lost an effort to stop U.S. sales of generic versions of its extended-release painkiller that don't have tamper-resistant qualities.

Impax Laboratories, Inc. today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, at 8:00 a.m. Pacific Standard Time.

Endo Health Solutions Inc. turned a first-quarter profit, reversing a lost at the start of 2012, when the drug developer absorbed a sizeable pre-tax charge tied to a settlement and license agreement.

Impax Laboratories Inc. delivered a profit and beat Wall Street's expectations, AND beat the revenue expectation.

The firm currently has a "neutral" rating on the stock. Shares of Impax Laboratories traded down 2.99% during mid-day trading on Thursday, hitting $16.85. Impax Laboratories has a 52 week low of $14.41 and a 52 week high of $27.25. The stock's 50-day moving average is currently $16.05. The company has a market cap of $1.117 billion and a P/E ratio ... (more)

Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $150,000 that they have only until May 6, 2013 to file lead plaintiff applications in a securities class action lawsuit against Impax Laboratories, Inc.

Good afternoon. My name is Stephanie, and I will be your conference operator today.

Impax Laboratories, Inc. today reported first quarter 2013 adjusted net income of $25.3 million or $0.37 per diluted share, compared to $35.8 million or $0.53 per diluted share in the first quarter 2012.

Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.

ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.

Andrew Richards remembers that he had just sat down in front of the TV when the lightning bolt struck.

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class comprising all purchasers of the common stock of Impax Laboratories, Inc.